"Remember, if he likes the drug and asks for another trial it will never be approved."
This is the drug's best chance IMO. It already took a LONG time to get these trials done, and DORB doesn't have a lot of resources.
"The fred Hutchinson center supplied 47 percent of the patients. since they use the corn oil they would not be able to do a placebo trial so a new trial would never recruit patients.""
One could almost make an argument then that the corn oil should be the placebo.
What hasn't been mentioned recently, and what I think is the biggest sticking point frankly in the data package, is the huge differential in the myelo's and the non-myelos. That has yet to be even plausibly explained, and adds to the concern that the observed survival data is an artifact.
Market Data 
Markets 
AI
